THERAPY DOSSIER · th-e1b2684c6385

Compound E

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21715616 ↗2011Mixed findings

Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-beta accumulation and independently accelerates the development of tau abnormalities.

MouseTBIControlled cortical impact3xTg-AD transgenicSystemicAfter TBI

Model: Controlled cortical impact traumatic brain injury

Gamma-secretase inhibition with Compound E blocked post-traumatic amyloid-beta accumulation but did not affect tau pathology after controlled cortical impact in 3xTg-AD mice.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…